Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511301 | 0.78 | QPCT (0.39) | PIK3CAALDH1A1GAASYKAURKA | |
| SCHEMBL9918974 | 0.77 | LMNA (0.38) | LMNADYRK1AALDH1A1PDE10AHTT | |
| SCHEMBL1997439 | 0.77 | ALDH1A1 (0.52) | ALDH1A1GAAHTTKMT2A | |
| SCHEMBL21304132 | 0.77 | ALDH1A1 (0.33) | PIK3CAALDH1A1GAASYKAURKA | |
| SCHEMBL21295143 | 0.77 | ALDH1A1 (0.33) | PIK3CAALDH1A1GAASYKAURKA | |
| SCHEMBL15624634 | 0.77 | NUDT1 (0.41) | PIK3CAAURKAKMT2A | |
| SCHEMBL10304905 | 0.76 | KMT2A (0.52) | LMNAALDH1A1PDE10ARECQLKMT2A | |
| SCHEMBL12093317 | 0.74 | LRRK2 (0.39) | LMNAALDH1A1PDE10AHTTKMT2A | |
| SCHEMBL19103239 | 0.74 | P2RX3 (0.37) | LMNAPDE10AHTTRECQLKMT2A | |
| SCHEMBL13004012 | 0.74 | GAA (0.40) | LMNAALDH1A1GAAPDE10AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2018112084-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9145426-B2 | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-8901125-B2 | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901125-B2 | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140023667-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck, Sharp & Dohme Corp. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130252943-A1 | BICYCLIC OXAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252943-A1 | BICYCLIC OXAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| WO-2013130639-A1 | BICYCLIC OXAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2012083224-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | LMNA 3929/4885PIK3CA 645/4885DYRK1A 3754/4885 |
| US-20130252943-A1 | BICYCLIC OXAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM1 | LMNA 4790/4885PIK3CA 560/4885DYRK1A 2388/4885 |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRIN3A | LMNA 4822/4885PIK3CA 613/4885DYRK1A 2422/4885 |
| US-20140023667-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, PSEN1, BACE2 | LMNA 1930/4885PIK3CA 1228/4885DYRK1A 1381/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | LMNA 3856/4885PIK3CA 621/4885DYRK1A 3722/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | LMNA 3929/4885PIK3CA 645/4885DYRK1A 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.